艺妙神州成立于2015年，总部位于北京，以“让癌症不再是绝症”为使命，是 一家领先的专注于以原研基因细胞药物技术应用于重大疾病（癌症、自身免疫性疾 病等）治疗的创新药企。截至目前，公司已完成10轮战略融资，拥有一站式自主基 因细胞药物研发和产业化平台，掌握多项核心技术，荣获全国颠覆性技术创新大赛 总决赛最高奖优胜奖，获批7项1类新药临床试验批准和北京首张基因细胞药物《药 品生产许可证》，研发管线覆盖淋巴瘤、白血病、骨髓瘤等血液肿瘤和肝癌、结直 肠癌、黑色素瘤等实体肿瘤，其中首个血液肿瘤CAR-T产品IM19针对复发难治弥漫 大B细胞淋巴瘤适应症已提交产品上市申请（NDA）并获得受理。

Founded in 2015 and headquartered in Beijing, Imunopharm is a leading  innovative pharmaceutical company dedicated to applying proprietary gene and cell  therapy technologies to treat major diseases (including cancer and autoimmune  diseases) with the mission of "making cancer no longer a fatal disease". To date,  the company has completed 10 rounds of strategic financing and established an  integrated in-house gene and cell drug R&D and industrialization platform. It has  mastered multiple core technologies and won the highest prize (Excellence Award)  at the National Disruptive Technology Innovation Competition finals. The company  has obtained 7 Class 1 New Drug Clinical Trial Approvals and Beijing's first genecell therapy Drug Manufacturing License. Its R&D pipeline covers hematologic  malignancies such as lymphoma, leukemia, myeloma, and solid tumors including  liver cancer, colorectal cancer, and melanoma.

地址：北京市海淀区杏石口80号益园文创基地B1号楼3层316号

3rd Floor, Building B1, Yiyuan, No.80 Xingshikou Road,

Haidian District, Beijing, China

电话：15901110706